Research programme: COMT inhibitors - CeNeS Pharmaceuticals
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator CeNeS Pharmaceuticals
- Developer Certara; PAION
- Class Small molecules
- Mechanism of Action Catechol O-methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease; Schizophrenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in United Kingdom (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Schizophrenia in United Kingdom (PO)
- 23 Jun 2008 CeNeS Pharmaceuticals has been acquired by PAION